CVS Health (CVS) Stock Forecast, Price Target & Predictions
CVS Stock Forecast
CVS Health stock forecast is as follows: an average price target of $103.77 (represents a 78.98% upside from CVS’s last price of $57.98) and a rating consensus of 'Hold', based on 24 wall street analysts offering a 1-year stock forecast.
CVS Price Target
The average price target for CVS Health (CVS) is $103.77 based on 1-year price targets from 24 Wall Street analysts in the past 3 months, with a price target range of $127.00 to $63.00. This represents a potential 78.98% upside from CVS's last price of $57.98.
CVS Analyst Ratings
According to 24 Wall Street analysts, CVS Health's rating consensus is 'Hold'. The analyst rating breakdown for CVS stock is 0 'Strong Buy' (0.00%), 10 'Buy' (41.67%), 13 'Hold' (54.17%), 1 'Sell' (4.17%), and 0 'Strong Sell' (0.00%).
CVS Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | George Hill | Deutsche Bank | $63.00 | $57.85 | 8.90% | 8.66% |
| Jun 28, 2024 | Brian Abrahams | RBC Capital | $74.00 | $58.58 | 26.33% | 27.63% |
| Jun 28, 2024 | Lisa Gill | J.P. Morgan | $86.00 | $58.58 | 46.82% | 48.33% |
| Jun 20, 2024 | Andrew Mok | Barclays | $65.00 | $61.01 | 6.54% | 12.11% |
| May 02, 2024 | Anton Hie | RBC Capital | $68.00 | $56.31 | 20.76% | 17.28% |
| Mar 15, 2024 | Jessica Tassan | Piper Sandler | $94.00 | $77.40 | 21.45% | 62.12% |
| Dec 12, 2023 | Erin Wright | Morgan Stanley | $100.00 | $73.76 | 35.57% | 72.47% |
| Sep 13, 2023 | David Macdonald | Truist Financial | $98.00 | $70.52 | 38.97% | 69.02% |
| Sep 12, 2023 | Justin Lake | Wolfe Research | $80.00 | $70.52 | 13.44% | 37.98% |
| Jul 12, 2023 | David Macdonald | Truist Financial | $103.00 | $71.27 | 44.52% | 77.65% |
The latest CVS Health stock forecast, released on Aug 08, 2024 by George Hill from Deutsche Bank, set a price target of $63.00, which represents a 8.90% increase from the stock price at the time of the forecast ($57.85), and a 8.66% increase from CVS last price ($57.98).
CVS Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 7 |
| Avg Price Target | - | $72.00 | $78.57 |
| Last Closing Price | $57.98 | $57.98 | $57.98 |
| Upside/Downside | -100.00% | 24.18% | 35.51% |
In the current month, the average price target of CVS Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CVS Health's last price of $57.98. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Sep 10, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Sep 06, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Aug 12, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Aug 12, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Aug 08, 2024 | Deutsche Bank | Hold | Hold | Hold |
| Aug 08, 2024 | Cantor Fitzgerald | Neutral | Neutral | Hold |
| Jul 23, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Jul 23, 2024 | UBS | Underperform | Underperform | Hold |
| Jul 08, 2024 | Zacks Investment Research | Outperform | Outperform | Hold |
CVS Health's last stock rating was published by RBC Capital on Sep 10, 2024. The company gave CVS a "Underperform" rating, the same as its previous rate.
CVS Health Financial Forecast
CVS Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $93.81B | $89.76B | $88.92B | $85.28B | $83.85B | $81.16B | - | $76.83B | $76.60B | $73.79B | $72.62B | $69.10B | $69.55B | $67.06B | $65.34B | $66.75B | $66.89B | $64.81B |
| Avg Forecast | $106.12B | $102.33B | $101.51B | $98.57B | $100.17B | $96.19B | $95.49B | $93.14B | $96.64B | $92.50B | $91.41B | $89.33B | $90.56B | $88.30B | $86.41B | $80.69B | $76.43B | $76.74B | $76.41B | $75.54B | $75.66B | $70.52B | $70.24B | $68.36B | $68.73B | $66.62B | $64.00B | $64.08B | $63.93B | $63.02B |
| High Forecast | $107.58B | $103.74B | $102.91B | $99.93B | $101.55B | $97.52B | $96.80B | $94.42B | $97.97B | $95.13B | $92.67B | $90.56B | $93.14B | $89.97B | $87.60B | $81.80B | $77.48B | $77.80B | $76.41B | $76.62B | $76.74B | $71.53B | $71.25B | $69.34B | $69.72B | $67.58B | $64.92B | $65.00B | $64.85B | $63.93B |
| Low Forecast | $103.43B | $99.74B | $98.93B | $96.07B | $97.63B | $93.75B | $93.06B | $90.78B | $94.19B | $89.93B | $89.09B | $87.06B | $87.83B | $85.13B | $84.21B | $78.64B | $74.49B | $74.79B | $76.41B | $74.36B | $74.48B | $69.42B | $69.14B | $67.29B | $67.66B | $65.58B | $63.00B | $63.08B | $62.93B | $62.04B |
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 8 | 19 | 18 | 9 | 8 | 8 | 12 | 16 | 18 | 9 | 9 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.02% | 1.03% | 1.06% | 1.10% | 1.06% | - | 1.02% | 1.01% | 1.05% | 1.03% | 1.01% | 1.01% | 1.01% | 1.02% | 1.04% | 1.05% | 1.03% |
CVS Health's average Quarter revenue forecast for Mar 24 based on 4 analysts is $89.33B, with a low forecast of $87.06B, and a high forecast of $90.56B. CVS's average Quarter revenue forecast represents a -4.78% decrease compared to the company's last Quarter revenue of $93.81B (Dec 23).
CVS Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 8 | 19 | 18 | 9 | 8 | 8 | 12 | 16 | 18 | 9 | 9 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $3.37B | $3.69B | $3.23B | $4.82B | $3.77B | $4.87B | - | $4.59B | $2.18B | $3.89B | $5.50B | $4.75B | $3.03B | $3.66B | $5.82B | $4.59B | $4.17B | $3.97B |
| Avg Forecast | $6.67B | $6.43B | $6.38B | $6.20B | $6.30B | $6.05B | $6.00B | $5.86B | $6.08B | $5.82B | $5.75B | $5.37B | $5.69B | $5.55B | $5.43B | $4.88B | $4.81B | $3.85B | $4.85B | $4.44B | $2.13B | $3.50B | $4.57B | $3.87B | $2.88B | $2.75B | $3.68B | $3.80B | $4.04B | $3.82B |
| High Forecast | $6.76B | $6.52B | $6.47B | $6.28B | $6.39B | $6.13B | $6.09B | $5.94B | $6.16B | $5.98B | $5.83B | $6.44B | $5.86B | $5.66B | $5.51B | $5.86B | $4.87B | $4.62B | $4.85B | $5.32B | $2.56B | $4.20B | $5.48B | $4.64B | $3.46B | $3.30B | $4.41B | $4.56B | $4.85B | $4.58B |
| Low Forecast | $6.50B | $6.27B | $6.22B | $6.04B | $6.14B | $5.89B | $5.85B | $5.71B | $5.92B | $5.65B | $5.60B | $4.29B | $5.52B | $5.35B | $5.30B | $3.90B | $4.68B | $3.08B | $4.85B | $3.55B | $1.71B | $2.80B | $3.66B | $3.09B | $2.31B | $2.20B | $2.94B | $3.04B | $3.23B | $3.05B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.59% | 0.66% | 0.60% | 0.99% | 0.78% | 1.26% | - | 1.03% | 1.02% | 1.11% | 1.20% | 1.23% | 1.05% | 1.33% | 1.58% | 1.21% | 1.03% | 1.04% |
4 analysts predict CVS's average Quarter EBITDA for Mar 24 to be $5.37B, with a high of $6.44B and a low of $4.29B. This is 59.16% upper than CVS Health's previous annual EBITDA (Dec 23) of $3.37B.
CVS Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 8 | 19 | 18 | 9 | 8 | 8 | 12 | 16 | 18 | 9 | 9 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $2.05B | $2.26B | $1.90B | $2.14B | $2.30B | $-3.41B | - | $2.31B | $1.30B | $1.60B | $2.78B | $2.22B | $973.00M | $1.22B | $2.98B | $2.01B | $1.75B | $1.53B |
| Avg Forecast | $2.61B | $2.77B | $2.78B | $2.16B | $2.40B | $2.50B | $2.50B | $1.83B | $2.14B | $2.17B | $2.19B | $2.71B | $2.51B | $2.68B | $2.66B | $2.46B | $2.42B | $1.58B | $2.76B | $2.24B | $1.27B | $1.44B | $2.31B | $1.81B | $925.92M | $920.30M | $1.88B | $1.66B | $1.70B | $1.47B |
| High Forecast | $2.66B | $2.82B | $2.83B | $2.20B | $2.44B | $2.54B | $2.55B | $1.86B | $2.17B | $2.35B | $2.23B | $3.25B | $2.54B | $2.78B | $2.71B | $2.95B | $2.46B | $1.90B | $2.76B | $2.68B | $1.52B | $1.72B | $2.77B | $2.17B | $1.11B | $1.10B | $2.26B | $1.99B | $2.03B | $1.76B |
| Low Forecast | $2.53B | $2.68B | $2.69B | $2.09B | $2.32B | $2.41B | $2.42B | $1.77B | $2.07B | $1.95B | $2.12B | $2.17B | $2.48B | $2.53B | $2.58B | $1.97B | $2.34B | $1.26B | $2.76B | $1.79B | $1.02B | $1.15B | $1.85B | $1.45B | $740.74M | $736.24M | $1.50B | $1.33B | $1.36B | $1.18B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.82% | 0.84% | 0.71% | 0.87% | 0.95% | -2.16% | - | 1.03% | 1.02% | 1.11% | 1.20% | 1.23% | 1.05% | 1.33% | 1.58% | 1.21% | 1.03% | 1.04% |
CVS Health's average Quarter net income forecast for Mar 24 is $2.71B, with a range of $2.17B to $3.25B. CVS's average Quarter net income forecast represents a 32.28% increase compared to the company's last Quarter net income of $2.05B (Dec 23).
CVS Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 8 | 19 | 18 | 9 | 8 | 8 | 12 | 16 | 18 | 9 | 9 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $12.99B | $12.52B | $12.42B | $12.06B | $12.26B | $11.77B | $11.68B | $11.40B | $11.83B | $11.32B | $11.19B | $10.93B | $11.08B | $10.81B | $10.57B | $9.87B | $9.35B | $9.39B | $9.36B | $9.25B | $9.27B | $8.64B | $8.60B | $8.37B | $8.42B | $8.16B | $7.84B | $7.85B | $7.83B | $7.72B |
| High Forecast | $13.17B | $12.69B | $12.59B | $12.23B | $12.43B | $11.93B | $11.85B | $11.55B | $11.99B | $11.64B | $11.34B | $11.08B | $11.40B | $11.01B | $10.72B | $10.01B | $9.48B | $9.52B | $9.36B | $9.39B | $9.40B | $8.76B | $8.73B | $8.49B | $8.54B | $8.28B | $7.95B | $7.96B | $7.94B | $7.83B |
| Low Forecast | $12.66B | $12.20B | $12.11B | $11.76B | $11.95B | $11.47B | $11.39B | $11.11B | $11.53B | $11.00B | $10.90B | $10.65B | $10.75B | $10.42B | $10.31B | $9.62B | $9.12B | $9.15B | $9.36B | $9.11B | $9.12B | $8.50B | $8.47B | $8.24B | $8.29B | $8.03B | $7.72B | $7.73B | $7.71B | $7.60B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
CVS Health's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CVS last annual SG&A of $NaN (undefined).
CVS Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 8 | 19 | 18 | 9 | 8 | 8 | 12 | 16 | 18 | 9 | 9 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.59 | $1.76 | $1.48 | $1.66 | $1.76 | $-2.59 | - | $1.76 | $0.98 | $1.21 | $2.11 | $1.69 | $0.74 | $0.93 | $2.27 | $1.54 | $1.34 | $1.17 |
| Avg Forecast | $2.08 | $2.20 | $2.21 | $1.72 | $1.91 | $1.98 | $1.99 | $1.45 | $1.70 | $1.73 | $1.74 | $1.70 | $1.99 | $2.13 | $2.12 | $2.10 | $1.92 | $2.00 | $2.18 | $2.17 | $1.85 | $1.79 | $2.07 | $1.73 | $1.24 | $1.33 | $1.91 | $1.62 | $1.68 | $1.77 |
| High Forecast | $2.11 | $2.24 | $2.25 | $1.75 | $1.94 | $2.02 | $2.02 | $1.48 | $1.73 | $1.87 | $1.77 | $1.73 | $2.02 | $2.21 | $2.15 | $2.14 | $1.96 | $2.03 | $2.18 | $2.21 | $1.88 | $1.82 | $2.10 | $1.76 | $1.26 | $1.35 | $1.95 | $1.66 | $1.71 | $1.80 |
| Low Forecast | $2.01 | $2.13 | $2.14 | $1.66 | $1.84 | $1.92 | $1.92 | $1.40 | $1.64 | $1.55 | $1.68 | $1.64 | $1.97 | $2.01 | $2.05 | $2.03 | $1.86 | $1.93 | $2.18 | $2.12 | $1.81 | $1.75 | $2.02 | $1.69 | $1.21 | $1.30 | $1.87 | $1.59 | $1.65 | $1.73 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | 0.83% | 0.70% | 0.79% | 0.92% | -1.30% | - | 0.81% | 0.53% | 0.68% | 1.02% | 0.98% | 0.60% | 0.70% | 1.19% | 0.95% | 0.80% | 0.66% |
According to 4 Wall Street analysts, CVS Health's projected average Quarter EPS for Mar 24 is $1.70, with a low estimate of $1.64 and a high estimate of $1.73. This represents a 6.63% increase compared to CVS previous annual EPS of $1.59 (Dec 23).
CVS Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CVS | CVS Health | $57.98 | $103.77 | 78.98% | Hold |
| HUM | Humana | $321.56 | $500.84 | 55.75% | Hold |
| CNC | Centene | $75.35 | $92.60 | 22.89% | Buy |
| ELV | Elevance Health | $550.84 | $556.91 | 1.10% | Buy |
| MOH | Molina Healthcare | $358.20 | $358.63 | 0.12% | Hold |
| UNH | UnitedHealth Group | $594.32 | $569.20 | -4.23% | Buy |
| CI | Cigna | $364.72 | $318.74 | -12.61% | Buy |
| ALHC | Alignment Healthcare | $11.89 | $9.50 | -20.10% | Buy |
CVS Forecast FAQ
Is CVS Health a good buy?
No, according to 24 Wall Street analysts, CVS Health (CVS) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 41.67% of CVS's total ratings.
What is CVS's price target?
CVS Health (CVS) average price target is $103.77 with a range of $63 to $127, implying a 78.98% from its last price of $57.98. The data is based on 24 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will CVS Health stock go up soon?
According to Wall Street analysts' prediction for CVS stock, the company can go up by 78.98% (from the last price of $57.98 to the average price target of $103.77), up by 119.04% based on the highest stock price target, and up by 8.66% based on the lowest stock price target.
Can CVS Health stock reach $90?
CVS's average twelve months analyst stock price target of $103.77 supports the claim that CVS Health can reach $90 in the near future.
What are CVS Health's analysts' financial forecasts?
CVS Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $384.99B (high $390.29B, low $375.22B), average EBITDA is $24.21B (high $24.54B, low $23.59B), average net income is $9.23B (high $9.39B, low $8.92B), average SG&A $47.11B (high $47.76B, low $45.92B), and average EPS is $7.33 (high $7.46, low $7.09). CVS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $408.54B (high $414.16B, low $398.17B), average EBITDA is $25.69B (high $26.04B, low $25.04B), average net income is $10.33B (high $10.51B, low $9.99B), average SG&A $49.99B (high $50.68B, low $48.72B), and average EPS is $8.2 (high $8.35, low $7.93).
Did the CVS's actual financial results beat the analysts' financial forecasts?
Based on CVS Health's last annual report (Dec 2023), the company's revenue was $357.78B, beating the average analysts forecast of $345.96B by 3.42%. Apple's EBITDA was $13.74B, missing the average prediction of $21.56B by -36.26%. The company's net income was $8.34B, missing the average estimation of $10.31B by -19.11%. Apple's SG&A was $0, missing the average forecast of $42.34B by -100.00%. Lastly, the company's EPS was $6.49, missing the average prediction of $8.34 by -22.20%. In terms of the last quarterly report (Dec 2023), CVS Health's revenue was $93.81B, beating the average analysts' forecast of $90.56B by 3.59%. The company's EBITDA was $3.37B, missing the average prediction of $5.69B by -40.77%. CVS Health's net income was $2.05B, missing the average estimation of $2.51B by -18.36%. The company's SG&A was $0, missing the average forecast of $11.08B by -100.00%. Lastly, the company's EPS was $1.59, missing the average prediction of $1.99 by -20.13%